Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.54 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.54 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30548041 | 0.79 | MAPK1 (0.51) | MAPK1MAP2K4MAPKAPK2MAPK6CYP1A2 | |
| SCHEMBL14631680 | 0.79 | MAPK1 (0.51) | MAPK1MAP2K4MAPKAPK2MAPK6CYP1A2 | |
| SCHEMBL28445675 | 0.79 | MAPK1 (0.60) | MAPK1MAP2K4MAPKAPK2MAPK6CYP1A2 | |
| SCHEMBL12866145 | 0.79 | MAP2K4 (0.51) | MAPK1MAP2K4MAPKAPK2MAPK6CYP1A2 | |
| SCHEMBL569660 | 0.79 | GAA (0.61) | MAPK1MAP2K4MAPKAPK2MAPK6ADRA2A | |
| SCHEMBL24455090 | 0.79 | MAPK1 (0.51) | MAPK1MAP2K4MAPKAPK2MAPK6CYP1A2 | |
| SCHEMBL31190844 | 0.79 | MAPK1 (0.51) | MAPK1MAP2K4MAPKAPK2MAPK6CYP1A2 | |
| SCHEMBL2614375 | 0.79 | GAA (0.61) | MAPK1MAP2K4MAPKAPK2MAPK6CYP1A2 | |
| SCHEMBL13701011 | 0.79 | CYP1A2 (0.43) | MAPK1MAP2K4MAPKAPK2MAPK6CYP1A2 | |
| SCHEMBL7737948 | 0.79 | CYP1A2 (0.43) | MAPK1MAP2K4MAPKAPK2MAPK6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137671-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | EXELIXIS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024112853-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | EXELIXIS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| WO-2022109179-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021262990-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3896064-A1 | 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS | Gilead Sciences, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3456717-B1 | 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVE AS CANCER OSAKA THYROID (COT) MODULATOR FOR TREATING INFLAMMATORY DISEASE | GILEAD SCIENCES INC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100216777-A1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON, INC. (CH) | 2010-08-26 | — | — | US | disclosed |
| US-7714017-B2 | for prostaglandin-mediated disorders; (E)-3-[1-(2,4-Dichloro-benzyl)-3,3-bis-hydroxymethyl-2-oxo-2,3-dihydro-1H-indol-7-yl]-acrylic acid | DECODE GENETICS, EHF (IS) | 2010-05-11 | — | — | US | disclosed |
| US-7714017-B2 | for prostaglandin-mediated disorders; (E)-3-[1-(2,4-Dichloro-benzyl)-3,3-bis-hydroxymethyl-2-oxo-2,3-dihydro-1H-indol-7-yl]-acrylic acid | DECODE GENETICS, EHF (IS) | 2010-05-11 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| CN-1144796-C | Intermediates and process for preparation of optically active octanoic acid derivs. | СҰҩƷ��ҵ��ʽ���� | 2004-04-07 | — | — | CN | disclosed |
| CN-1309652-A | Intermediates and process for preparation of optically active octanoic acid derivs. | ONO PHARMACEUTICAL CO (JP) | 2001-08-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, RUNX1, ACIN1 | MAPK1 2841/4885MAP2K4 4829/4885MAPKAPK2 4774/4885 |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | MAPK1 146/4885MAP2K4 340/4885MAPKAPK2 1080/4885 |
| US-20100216777-A1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOA | MAPK1 311/4885MAP2K4 735/4885MAPKAPK2 42/4885 |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GPER1, ESR2, ESRRB | MAPK1 4030/4885MAP2K4 4188/4885MAPKAPK2 2979/4885 |
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, CYP11B1, CYP4A11 | MAPK1 65/4885MAP2K4 672/4885MAPKAPK2 364/4885 |
| US-20090192154-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, ADAMTS1 | MAPK1 2815/4885MAP2K4 4857/4885MAPKAPK2 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.